LoginRegister

    Cadila Healthcare largest API manufacturing site clears USFDA inspection

    Medical Dialogues BureauWritten by Medical Dialogues Bureau   |  

    The US Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredients (API) manufacturing facility at Dabhasa from October 7 to October 11, 2019, Cadila Healthcare said in a statement.


    New Delhi: Drug firm Cadila Healthcare on Friday said the US health regulator issued no observations after the inspection of its Dabhasa facility in Gujarat.


    The US Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredients (API) manufacturing facility at Dabhasa from October 7 to October 11, 2019, Cadila Healthcare said in a statement.


    Also Read: Cadila Healthcare gets OAI letter from USFDA for Moraiya facility


    Dabhasa facility is the company's largest API manufacturing site, it added.


    "This was a current good manufacturing practice (cGMP) audit and a pre-approval inspection (PAI). At the end of the inspection, no observation (483) is issued," Cadila Healthcare said.


    Headquartered at Ahmedabad, Cadila's Dabhasa plant API/Bulk Drug Plant in a village about 20 kilometres South from Vadodara houses one of the largest process research (API) centres in that country. This plant belonged to Banyan Chemicals which was acquired by Zydus in 2003.


    Also Read: Cadila Healthcare to sell right of cholesterol-lowering drug Zypitamag for Rs 49 crore

    APICadilacadila dabhasaCadila HealthcarecGMPcurrent good manufacturing practiceDabhasa facilityDabhasa plantform 483gujarat facilityPAI inspectionpharmapharma companypharma newspharma news indiapre-approval inspectionUS Food and Drug AdministrationUS health regulatorUSFDAUSFDA inspectionZydus Cadila
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      sidekick